P

    Pmv Pharmaceuticals Inc (PMVP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.21
    -0.01 (-0.82%)

    Market Cap: $65.22M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    63%(15/24)
    Avg Surprise
    +6.51%
    Streak
    4 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.39
    Range$-0.41 - $-0.36
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.35+8.2%
    60d ago$-0.35+8.2%
    30d ago$-0.35+8.2%
    7d ago$-0.35+8.2%
    Current$-0.39
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Dec 31, 2026
    EPS Consensus$-0.24
    Range$-0.25 - $-0.23
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.24---
    Sep 26EST
    		-$-0.39---
    Jun 26
    		$-0.34$-0.38+10.53%Beat+17.1%
    Mar 26
    		$-0.34$-0.38+10.53%Beat+0.0%
    Dec 25
    		$-0.34$-0.41+18.07%Beat+24.4%
    Sep 25
    		$-0.40$-0.40+0.00%Beat-8.1%
    Jun 25
    		$-0.41$-0.39-5.13%Miss-1950.0%
    Mar 25
    		$-0.34$-0.38+10.53%Beat-13.3%
    Dec 24
    		$-0.45$-0.38-18.42%Miss-45.2%
    Sep 24
    		$-0.37$-0.36-2.78%Miss-8.8%
    Jun 24
    		$-0.02N/A+94.44%Beat+94.7%
    Mar 24
    		$-0.30$-0.37+18.92%Beat+28.6%
    Dec 23
    		$-0.31$-0.39+20.51%Beat+27.9%
    Sep 23
    		$-0.34$-0.45+24.44%Beat+15.0%
    Jun 23
    		$-0.38$-0.47+19.15%Beat+0.0%
    Mar 23
    		$-0.42$-0.46+8.70%Beat-2.4%
    Dec 22
    		$-0.43$-0.44+2.27%Beat-7.5%
    Sep 22
    		$-0.40$-0.41+2.44%Beat-21.2%
    Jun 22
    		$-0.38$-0.41+7.32%Beat-31.0%
    Mar 22
    		$-0.41$-0.39-5.13%Miss-57.7%
    Dec 21
    		$-0.40$-0.35-14.29%Miss+36.5%
    Sep 21
    		$-0.33$-0.30-10.00%Miss+49.2%
    Jun 21
    		$-0.29$-0.28-3.57%Miss+39.6%
    Mar 21
    		$-0.26$-0.24-8.33%Miss-
    Dec 20
    		$-0.63$-0.67+5.97%Beat-
    Sep 20
    		$-0.65$-0.50-30.00%Miss-
    Jun 20
    		$-0.48$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.85EV/EBITDA1.24x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-70.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage17.78x
    Current Ratio7.70xQuick Ratio7.70x
    Trading Statistics
    Beta1.35Avg Volume304.25K
    52-Week High$1.8852-Week Low$1.02

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.27
    SMA 20$1.25
    SMA 50$1.24
    SMA 200$1.27
    EMA 10$1.26
    EMA 20$1.25
    EMA 50$1.24
    EMA 200$1.27

    MACD

    Line: 0.01Signal: 0.01Hist: -0.01

    ADX

    ADX: 13.1+DI: 18.5-DI: 22.0

    Aroon & PSAR

    Aroon Up80.0
    Aroon Down20.0
    PSAR$1.35

    Bollinger Bands

    Upper Band$1.35
    Lower Band$1.15
    %B Position1606%(Upper)
    Band Width0.31

    RSI (14-Day)

    Neutral
    45.3

    Momentum Oscillators

    Stoch %K15.6
    Stoch %D39.7
    Williams %R-100.0
    ROC (10d)-3.2%
    Momentum-0.04
    CCI (20d)-46.9
    MFI (14d)43.3

    Volatility Measures

    ATR (14d)$0.06(5.0%)
    StdDev (20d)0.05
    Hist Vol45.0%(High)

    Volume Flow

    VWAP$1.22
    OBV-18.6M
    AD Line-32.9M
    CMF (20d)-0.148

    Volume Metrics

    Avg Vol (20d)214.2K
    Vol Ratio3.2x(High)
    VWMA (20d)$1.25

    Pivot Points

    R3$1.28
    R2$1.26
    R1$1.24
    Pivot Point$1.23
    S1$1.21
    S2$1.19
    S3$1.17

    Advanced Oscillators

    TSI3.79
    Ultimate Osc31.9
    KST44.94

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$1.62M$0
    Cost of Revenue$0$0$33,000$0$0$0N/A$0$0$0$359,000$0
    Gross Profit$0$0$-33,000$0$0$0N/A$0$0$0$-359,000$0
    Operating Expenses$18.88M$19.02M$19.24M$22.52M$22.88M$21.56M$25.17M$21.89M$20.17M$18.22M$18.90M$19.63M
    R&D$14.68M$15.33M$15.83M$18.21M$18.40M$17.44M$13.77M$16.95M$14.63M$13.19M$13.38M$13.59M
    SG&A$4.21M$3.69M$3.42M$4.31M$4.48M$4.12M$11.40M$4.94M$5.54M$5.04M$5.52M$6.04M
    Operating Income$-18,881,000$-19,019,000$-19,241,000$-22,522,000$-22,879,000$-21,564,000$-25,169,000$-21,888,000$-20,170,000$-18,221,000$-18,902,000$-19,628,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$-788,000$-980,000$-1,232,000$-1,480,000$-1,690,000$-1,935,000$-2,287,000$-2,615,000$-2,801,000$-2,952,000$-3,166,000$-2,984,000
    Income Before Tax$-18,083,000$-18,038,000$-18,011,000$-21,065,000$-21,205,000$-19,633,000$-23,001,000$-19,152,000$-17,386,000$-15,270,000$-15,758,000$-16,640,000
    Income Tax Expense$3,000$0$26,000$-6,000$5,000$-2,197,000$-1,000$74,000$-16,173,000$0$-2,000$0
    Net Income$-18,086,000$-18,038,000$-18,037,000$-21,059,000$-21,210,000$-17,436,000$-23,000,000$-19,226,000$-1,213,000$-15,270,000$-15,756,000$-16,640,000
    EBITDA$-19,229,000$-19,370,000$-19,721,000$-23,208,000$-23,587,000$-22,367,000$-26,262,000$-22,631,000$-21,191,000$-19,488,000$-20,418,000$-21,108,000
    EBIT$-18,871,000$-19,019,000$-19,241,000$-22,545,000$-22,895,000$-21,564,000$-25,169,000$-21,767,000$-20,187,000$-18,222,000$-18,902,000$-19,624,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PMVP

    News

    ETFs Investing in PMV Pharmaceuticals, Inc. Stocks

    This article provides a list of ETFs that invest in PMV Pharmaceuticals, Inc. (PMVP) stocks, sorted by market value. It highlights the Bridgeway Ultra-Small Company Market ETF (BUSM) as a fund holding PMVP, detailing its market value, weight, expense ratio, and performance. The information aims to make investing in such stocks more accessible and offer diversified opportunities.

    TradingView•8/21/26•
    Neutral

    PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?

    PMV Pharmaceuticals (PMVP) has been upgraded to a Zacks Rank #2 (Buy), driven primarily by an upward trend in its earnings estimates. The Zacks rating system highlights the strong correlation between changing earnings pictures and near-term stock price movements, suggesting a positive outlook for PMVP's stock. This upgrade indicates an improvement in the company's underlying business and places PMV Pharmaceuticals among the top 20% of Zacks-covered stocks based on superior earnings estimate revisions.

    Yahoo Finance•8/19/26•
    Bullish

    Form 8K Pmv Pharmaceuticals Inc For: 14 August By Investing.com

    This article reports on the filing of a Form 8K by PMV Pharmaceuticals Inc. on August 14, 2026. The Form 8K filing is a routine SEC disclosure for significant corporate events. The stock symbol PMVP is noted with a 3.70% increase.

    Investing.com Nigeria•8/15/26•
    Neutral

    PMV Pharmaceuticals Releases Q2 2026 Financial Results

    PMV Pharmaceuticals reported a narrower loss for Q2 2026, with a loss of $0.34 per share compared to $0.41 in the prior year, marking a 17.1% improvement. The company focuses on precision oncology, developing therapies for p53 mutations, and maintains a positive analyst consensus despite being pre-revenue. This reflects confidence in its targeted approach and progress in expense management while advancing research.

    AlphaStreet•8/15/26•
    Somewhat-Bullish

    PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

    PMV Pharmaceuticals announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company completed enrollment for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial for platinum-resistant/refractory ovarian cancer and plans to submit an NDA for rezatapopt in the first quarter of 2027. PMV Pharma reported $79.4 million in cash, cash equivalents, and marketable securities, with an expected cash runway through the second quarter of 2027.

    GlobeNewswire•8/15/26•
    Somewhat-Bullish

    Frequently Asked Questions About PMVP

    Does PMVP pay dividends?
    Pmv Pharmaceuticals Inc (PMVP) does not currently pay a regular dividend.
    What is PMVP's market cap?
    Pmv Pharmaceuticals Inc (PMVP) has a market capitalization of $65.22M with a current stock price of $1.21.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In